表紙:勃起不全(女性・男性の健康):開発中の薬剤(2021年)
市場調査レポート
商品コード
1000867

勃起不全(女性・男性の健康):開発中の薬剤(2021年)

Erectile Dysfunction (Women's and Male Health) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 165 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
勃起不全(女性・男性の健康):開発中の薬剤(2021年)
出版日: 2021年03月31日
発行: Global Markets Direct
ページ情報: 英文 165 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

勃起不全、またはEDは、男性が性交をするのに十分なほどの勃起をすることができないことです。病因には、喫煙、肥満、怪我、薬物とアルコールの使用、および高血圧、抗うつ薬、抗ヒスタミン薬、痛みまたは前立腺癌を治療するための薬剤療法が挙げられます。

当レポートは、勃起不全(女性・男性の健康)の開発中の薬剤について調査しており、世界の治療情勢、開発段階、薬剤ターゲット、作用機序(MoA)、投与経路(RoA)、分子タイプなどの分析、主要企業のレビュー、勃起不全の治療に関する最新ニュースやプレスリリース等の包括的な情報を提供しています。

目次

  • イントロダクション
  • 勃起不全-概要
  • 勃起不全-治療法の開発
  • 勃起不全-治療評価
  • 勃起不全-治療法開発に関与する企業
  • 勃起不全-薬剤プロファイル
  • 勃起不全-休眠プロジェクト
  • 勃起不全-製造中止製品
  • 勃起不全-製品開発のマイルストーン
  • 付録
図表

List of Tables

  • Number of Products under Development for Erectile Dysfunction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Erectile Dysfunction - Pipeline by AnyGen Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Aprogen Inc, 2021
  • Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, 2021
  • Erectile Dysfunction - Pipeline by Astellas Pharma Inc, 2021
  • Erectile Dysfunction - Pipeline by Benuvia Therapeutics Inc, 2021
  • Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, 2021
  • Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2021
  • Erectile Dysfunction - Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Cure Pharmaceutical Inc, 2021
  • Erectile Dysfunction - Pipeline by Dicot AB, 2021
  • Erectile Dysfunction - Pipeline by Exopharm Ltd, 2021
  • Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2021
  • Erectile Dysfunction - Pipeline by Farmalider SA, 2021
  • Erectile Dysfunction - Pipeline by Guangzhou Four-Leaf Clover HealthTech Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Hemostemix Inc, 2021
  • Erectile Dysfunction - Pipeline by Humanetics Corp, 2021
  • Erectile Dysfunction - Pipeline by ILGEN Inc, 2021
  • Erectile Dysfunction - Pipeline by Initiator Pharma AS, 2021
  • Erectile Dysfunction - Pipeline by IntelGenx Corp, 2021
  • Erectile Dysfunction - Pipeline by Klaria Pharma Holding AB, 2021
  • Erectile Dysfunction - Pipeline by MannKind Corp, 2021
  • Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by MicroCures Inc, 2021
  • Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Erectile Dysfunction - Pipeline by MyX Therapeutics Inc, 2021
  • Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, 2021
  • Erectile Dysfunction - Pipeline by Organicell Regenerative Medicine Inc, 2021
  • Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Reven Pharmaceuticals Inc, 2021
  • Erectile Dysfunction - Pipeline by Seelos Therapeutics, Inc., 2021
  • Erectile Dysfunction - Pipeline by siRNAgen Therapeutics Corp, 2021
  • Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, 2021
  • Erectile Dysfunction - Pipeline by Targazyme Inc, 2021
  • Erectile Dysfunction - Pipeline by Tavanta Therapeutics Inc, 2021
  • Erectile Dysfunction - Pipeline by Techfields Pharma Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Venturis Therapeutics Inc, 2021
  • Erectile Dysfunction - Pipeline by Veru Inc, 2021
  • Erectile Dysfunction - Pipeline by XuanZhu Biological Technology Co Ltd, 2021
  • Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, 2021
  • Erectile Dysfunction - Dormant Projects, 2021
  • Erectile Dysfunction - Dormant Projects, 2021 (Contd..1)
  • Erectile Dysfunction - Dormant Projects, 2021 (Contd..2)
  • Erectile Dysfunction - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Erectile Dysfunction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC12814IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Drugs in Development, 2021, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 2, 9, 5, 15, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Erectile Dysfunction - Overview
  • Erectile Dysfunction - Therapeutics Development
  • Erectile Dysfunction - Therapeutics Assessment
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
  • Erectile Dysfunction - Drug Profiles
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones
  • Appendix